Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Small Molecule Antagonists of the MDM2 Oncoprotein as Anticancer Agents

1 Feb 2005

Abstract excerpt

In this early phase of the new era of molecularly targeted patient friendly cancer chemotherapy, there is a need for novel viable anticancer molecular targets. The MDM2 oncoprotein has been validated as a potential target for cancer drug development. MDM2 amplification and/or overexpression occur in a wide variety of human cancers, several of which can be treated experimentally with MDM2 antagonists. MDM2...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer-related Molecular Pathways
Share to Cancer Research and Treatments
Share to Ubiquitin and proteasome pathways

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 15720190
DOI: 10.2174/1568009053332672

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Small Molecule Antagonists of the MDM2 Oncoprotein as Anticancer AgentsPMID 15720190Read ↗

In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2Semantic proximity Read ↗

Targeting p53-MDM2 Interaction Using Small Molecule Inhibitors and the Challenges Needed to be AddressedSemantic proximity Read ↗

Natural Product MDM2 Inhibitors: Anticancer Activity and Mechanisms of ActionSemantic proximity Read ↗

Small-molecule inhibitors of the p53-HDM2 interaction for the treatment of cancerSemantic proximity Read ↗

Targeting the p53–MDM2 interaction to treat cancerSemantic proximity Read ↗

MDM2 Antagonists and p53-Targeting Therapies in Cancer: Clinical Applications, Adverse Effects, and Resistance MechanismsSemantic proximity Read ↗

Small-Molecule Antagonists of p53-MDM2 Binding: Research Tools and Potential TherapeuticsSemantic proximity Read ↗

Mdm2 and MdmX inhibitors for the treatment of cancer: a patent review (2011 – present)Semantic proximity Read ↗

Targeting p53–MDM2 interaction by small-molecule inhibitors: learning from MDM2 inhibitors in clinical trialsSemantic proximity Read ↗

Small Molecule Inhibitors of the p53-MDM2Semantic proximity Read ↗

Recent Advances in Validating MDM2 as a Cancer TargetSemantic proximity Read ↗

p53–Mdm2 inhibitors: patent review (2009 – 2010)Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.